摘要
目的基于整合药理学预测二至丸治疗高血压的分子机制。方法基于整合药理学,通过TCMSP中草药药理学平台及GeneCards数据库,筛选出二至丸治疗高血压的活性成分及对应靶点,基于Cytoscape 3.7.2软件构建相关网络,对降压机制进行预测分析。结果获得二至丸治疗高血压的关键成分为槲皮素、木犀草素;核心靶点主要涉及丝氨酸苏氨酸蛋白激酶1(AKT1)、白细胞介素-6(IL6)、血管内皮生长因子A(VEGFA)、胱天蛋白酶3(CASP3)、肿瘤坏死因子(TNF)、表皮生长因子受体(EGFR)等;关键通路为肿瘤坏死因子信号通路(TNF signaling pathway)、缺氧诱导因子1信号通路(HIF-1 signaling pathway)、磷脂酰肌醇3-激酶/蛋白激酶B信号通路(PI3K-Akt signaling pathway)、血管内皮生长因子信号通路(VEGF signaling pathway)、丝裂原活化蛋白激酶信号通路(MAPK signaling pathway)等。结论二至丸具有多靶点、多通路治疗高血压的特点,二至丸降压治疗的药效成分、作用靶点、分子通路可为进一步深入揭示其作用机制奠定基础。
Objective To predict the molecular mechanism of Erzhiwan in treating hypertension based on integrated pharmacology.Methods Based on integrated pharmacology,the active ingredients and corresponding targets of Erzhiwan in the treatment of hypertension were selected through TCMSP Chinese herbal pharmacology platform and GeneCards database.The related network was constructed based on Cytoscape 3.7.2 software to predict and analyze the antihypertensive mechanism.Results The key components of Erzhiwan were quercetin and luteolin.The core targets were serine threonine protein kinase 1(AKT1),interleukin-6(IL6),vascular endothelial growth factor A(VEGFA),Caspase3(CASP3),tumor necrosis factor(TNF)and epidermal growth factor receptor(EGFR).The key pathways were TNF signaling pathway,hoxia-inducible factor 1 signaling pathway(HIF-1 signaling pathway),Phosphatidylinositol 3-kinase/protein kinase B signaling pathway(PI3K-Akt signaling pathway),VEGF signaling pathway,mitogen-activated protein kinase signaling pathway(MAPK signaling pathway)and other pathways.Conclusion Erzhiwan had the characteristics of multi-target and multi-channel treatment of hypertension.The pharmacodynamic components,action targets,and molecular pathways of Erzhiwan in antihypertensive treatment supplied laid a foundation for further revealing its mechanism of action.
作者
李梓源
罗植允
冯晶晶
吴伟
LI Ziyuan;LUO Zhiyun;FENG Jingjing;WU Wei(The First Clinical College,Guangzhou University of Chinese Medicine,Guangzhou 510006,Guangdong,China)
出处
《中西医结合心脑血管病杂志》
2022年第12期2130-2134,共5页
Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
关键词
高血压
二至丸
整合药理学
分子机制
hypertension
Erzhiwan
integrated pharmacology
molecular mechanism
